Is It Too Late to Rebuild Bone After 60? What the Trials Show

Where the too-late belief comes from

By 60 a lot of women have quietly given up on their bones. The scan number drifts down each visit, the advice stays the same, and the emotional conclusion sets in that the damage is done and the job now is just to fall carefully.

That belief is understandable, and it comes from a real place. The most common bone medications are designed to slow how fast you take bone apart. They are a brake. On a brake, the best case is that the line falls more slowly. Nobody promises the line will climb, so a woman reasonably concludes that climbing is not on the table, especially not after 60.

But the too-late belief is about the tools, not the bone. The bone itself has not stopped being able to rebuild. It is waiting on an instruction it stopped receiving.

Why bone can still be rebuilt at any age

Here is the biology that makes rebuilding possible late.

Bone is never finished. Every day of your life, cells break a little of it down and other cells build a little back. This remodeling does not stop at 40 or 60 or 80. What changes after menopause is the balance. With estrogen gone, the breakdown crew outworks the building crew, and the net direction turns to loss.

That balance is not a one-way ratchet. Shift the signal so the building crew keeps pace again, and the direction can turn back the other way. Age narrows the margin, but it does not close the door, because the machinery that lays down new bone is still there and still working. It just needs to be told to.

What the trial found in women past menopause

This is where the research answers the question directly, because it was run on exactly this population.

The trial was published in 2022 in Phytomedicine by Pingali and Nutalapati, at Nizam's Institute of Medical Sciences in Hyderabad. It enrolled 60 postmenopausal women with low bone mass, ran 48 weeks, and was randomized, double blind, and placebo controlled. The women were split into placebo, 250 mg a day of purified shilajit, and 500 mg a day.

The placebo group did the expected thing. Their bone density fell at both the spine and the hip. Both shilajit groups went the other way. Density was preserved and increased from each woman's starting point, the higher dose did more, and every single woman who took it reversed her osteopenia.

There is a second piece of human evidence worth adding here. A 2020 double-blind randomized controlled trial in 160 people (Sadeghi and colleagues) found that oral shilajit, known regionally as momiai, cut the average tibial-fracture healing time to about 129 days versus 153 days on placebo, roughly 24 days faster https://pubmed.ncbi.nlm.nih.gov/32310691/. That is human evidence of shilajit actively supporting bone rebuilding, not just slowing loss.

Rebuild versus brake, read in the blood

The difference between rebuilding and slowing loss is not a word game. The trial measured it in the blood.

CTX-1, the marker of bone being torn down, rose in the placebo group and fell by about 22 percent in the 500 mg shilajit group. Then the pair that governs direction, RANKL and OPG. RANKL tells the body to dismantle bone. OPG protects it. On shilajit, OPG rose by about 57 percent and the RANKL to OPG ratio fell by about 42 percent. A brake would only slow the dismantling. This shifted the whole instruction toward protection and building, which is why the density rose instead of merely falling slower.

Why it works on the signal, not the hormone

Women are right to be cautious about anything touching estrogen, so the frame matters.

Shilajit is not a hormone and does not add estrogen to your body. After menopause the estrogen signal that keeps bone in rebuild mode goes quiet, and that quiet signal is what turns the balance toward loss. Shilajit supports the body's own estrogen signaling and shifts the breakdown to build ratio, working with your own machinery rather than replacing a hormone. That is why the same women who cannot or will not take a hormone can still address the signal that fell.

The mechanism underneath

The human result rests on consistent earlier work. Kangari and colleagues in 2022 found shilajit accelerated the maturation of human stem cells into bone building cells. Abbasi and colleagues in 2019 found a low dose raised osteoblast proliferation. In ovariectomized rats, a standard menopause model, shilajit raised density and lowered turnover markers. None of these replace the human trial. They explain why bone at any responsive age can still be built when the signal is restored.

Safety and purity

The trial safety read was clean, all labs normal and no dropouts for side effects, and across every human shilajit study, zero serious adverse events have been reported.

Optimum shilajit is from the Altai mountains, cold pressed and purified, independent third party lab tested, heavy metal free, and Prop 65 compliant in California. We are a small, family owned company out of Florida, and it comes as a box of tablets.

What this means for you

If you are past 60 and have written your bones off, the trial is a reason to reconsider. Not a promise, and not a claim that age is irrelevant. A published human result in postmenopausal women, showing that the scan can move up when the rebuild signal is restored. The door you thought had closed was the door on the old tools, not on your bone.

References

1. Pingali U, Nutalapati C. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial. Phytomedicine. 2022;105:154334. https://pubmed.ncbi.nlm.nih.gov/35933897/
2. Kangari P, et al. Shilajit accelerates osteogenic differentiation of human adipose-derived stem cells. 2022. https://pubmed.ncbi.nlm.nih.gov/36153551/
3. Abbasi A, et al. Effect of mumie on proliferation of osteoblast-like cells. 2019. https://pubmed.ncbi.nlm.nih.gov/31983854/
4. Alshubaily F, et al. Antioxidant and anti-osteoporotic activities of shilajit-loaded chitosan nanoparticles in rats. 2022. https://pubmed.ncbi.nlm.nih.gov/36235920/
5. Stohs SJ. Safety and efficacy of shilajit (mumie, moomiyo). Phytotherapy Research. 2014. https://pubmed.ncbi.nlm.nih.gov/23733436/
6. Sadeghi SMH, et al. "The effect of momiai (shilajit) on fracture healing: a randomized, double-blind, placebo-controlled clinical trial." 2020. n=160; healing time about 129 days vs 153 days on placebo. PMID 32310691. (Paywalled, URL cited.)